John Kirkwood

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, John Kirkwood sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials 2 currently recruiting 3 completed early-phase tilt upper quartile by trial count

John Kirkwood: 8 sponsored US clinical trials, 2 recruiting.

John Kirkwood sponsors 8 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 3 completed. 0 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Locally Advanced Melanoma, with 1 trials.

Upper-quartile sponsor footprint

John Kirkwood sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

8 total, page 1 of 1

RECRUITING

Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma

NCT07223411
RECRUITING

Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi

NCT06599619
NOT YET RECRUITING Phase 1

Axelopran in Patients With Anti-PD-1 Refractory Metastatic or Locoregionally Unresectable Cutaneous Melanoma

NCT07631325
TERMINATED Phase 1

Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma

NCT04688658
COMPLETED Phase 2

Nivolumab, BMS-936558 in Combination with Relatlimab, BMS-986016 in Patients with Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting

NCT03743766
COMPLETED Phase 1

Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma

NCT01943422
COMPLETED Early Phase 1

Pilot Study Evaluating Sulforaphane in Atypical Nevi-Precursor Lesions

NCT01568996
TERMINATED Phase 2

Dendritic Cells (DC) Vaccine for Metastatic Melanoma

NCT01042366

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 2

Therapeutic Areas

Locally Advanced Melanoma 1
Melanoma 1

What is open in the John Kirkwood pipeline

2 recruiting of 8 indexed (25% open); 3 completed (38%).

Phase mix: 0 late (III/IV) vs 6 early (I/II) (early-phase heavy).

Top condition: Locally Advanced Melanoma (1 trial), 1 other listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

John Kirkwood: open-pipeline peers nationwide

Peers matched on 8 registered trials and 25% open enrollment, not the therapeutic-area sidebar.

John Kirkwood sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 3456789 0%10%20%30%40% Total trials Recruiting share John KirkwoodAB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Abdul Latif Jameel Poverty Action LabAccutar BiotechnologyAdrienne G. WaksAdvocate Hospital System
John Kirkwood sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

John Kirkwood sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 trials (± recruiting share)

Sponsors near 25% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this John Kirkwood page

8 registered trials is a research-attention snapshot, not an endorsement of John Kirkwood or any single study.

  • 2 of John Kirkwood's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Locally Advanced Melanoma is the condition John Kirkwood studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Locally Advanced Melanoma trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

John Kirkwood pipeline card: 8 registered trials from official public datasets.Report a data error.